Sarcopenic Obesity: Time to Meet the Challenge
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
The prevalence of overweight and obesity has reached epidemic proportions worldwide due to increasingly pervasive obesogenic lifestyle changes. Obesity poses unprecedented individual, social, and multidisciplinary medical challenges by increasing the risk for metabolic diseases, chronic organ failures, and cancer as well as complication rates in the presence of acute disease conditions. Whereas reducing excess adiposity remains the fundamental pathogenic treatment for obese individuals, complex metabolic and lifestyle abnormalities as well as weight reduction therapies per se may also compromise the ability to preserve muscle function and mass, especially when chronic disease co-exists with obesity. Emerging evidence indicates that low muscle mass and quality have a strong negative prognostic impact in obese individuals and may lead to frailty, disability, and increased morbidity and mortality. Awareness of the importance of skeletal muscle maintenance in obesity is however low among clinicians and scientists. The term ‘sarcopenic obesity' has been proposed to identify obesity with low skeletal muscle function and mass, but its utilization is largely limited to the aging patient population, and consensus on its definition and diagnostic criteria remains insufficient. Knowledge on prevalence of sarcopenic obesity in various clinical conditions and patient subgroups, on its clinical impacts in patient risk stratification, and on effective prevention and treatment strategies remain therefore dramatically inadequate. In particular, optimal dietary options and medical nutritional support strategies to preserve muscle mass in obese individuals remain largely undefined. The European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) recognize and indicate obesity with altered body composition due to low skeletal muscle function and mass (sarcopenic obesity) as a scientific and clinical priority for researchers and clinicians. ESPEN and EASO therefore call for coordinated action aimed at reaching consensus on its definition, diagnostic criteria, and optimal treatment with particular regard to nutritional therapy. We are convinced that achievement of these goals has a strong potential to reduce the burden of morbidity and mortality in the rapidly increasing obese patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consensus statements have emphasized that SO should be understood as a disorder of body composition and function rather than as a simple coexistence of two diagnoses (1, 2).”
From Exercise-based interventions for sarcopenic obesity in middle-aged and older adults: an umbrella review of systematic reviews with pairwise meta-analyses and network meta-analyses (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“cytokines produced by infiltrating cells such as macrophages can cause muscular atrophy by inducing filament protein degradation and apoptosis (21).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [21]
In the citing paper
“Indeed, there are multiple biological effects of physical activity: promote insulin sensitivity, improve anabolic response to endogenous amino acids, activate skeletal muscle satellites cells and trigger the proliferation and differentiation of them, amplify irisin production, adjust hormonal milieu, increase mitochondrial biogenesis, ameliorate inflammation and reduce oxidative stress (162–164).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Self-citationThe metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“…: clustered metabolic de-rangements including systemic and muscle oxidative stress, in fl ammation and insulin resistance may occur in obesity [17 e 20] due to various causes that primarily include a) excess nutrient availability and tissue delivery, particularly saturated fat [28] and…”
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058 · cited 2×
“Reducing excess adiposity remains the fundamental pathogenetic treatment for obese individuals [15,16].”
McClave, S. A., Taylor, B. E., Martindale, R. G., Warren, M. M., Johnson, D. R., Braunschweig, C., McCarthy, M. S., Davanos, E., Rice, T. W., Cresci, G. A., et al. (2016) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607115621863 · Cited by 3,982
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Self-citationGlobal burden of obesity in 2005 and projections to 2030
Kelly, T., Yang, W., Chen, C.-S., Reynolds, K., & He, J. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.102 · Cited by 3,319
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70153-0 · Cited by 3,238 · cited 1×
“Indeed low or declining muscle mass is emerging as a negative prognostic factor associated with higher morbidity and mortality in obese patients with chronic diseases [67 e 69].”
Cited by
Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Obesity Facts · doi:10.1159/000521241 · Cited by 1,019
Self-citationDefinition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement
Donini, L. M., Busetto, L., Bischoff, S. C., Cederholm, T., Ballesteros-Pomar, M. D., Batsis, J. A., Bauer, J. M., Boirie, Y., Cruz-Jentoft, A. J., Dicker, D., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2021.11.014 · Cited by 566
Self-citationDonini, L. M., Busetto, L., Bauer, J. M., Bischoff, S., Boirie, Y., Cederholm, T., Cruz-Jentoft, A. J., Dicker, D., Frühbeck, G., Giustina, A., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2019.11.024 · Cited by 326
“In recent years, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) have issued joint statements calling for further collaborative efforts aimed at overcoming existing hurdles towards clinical applicability of the sarcopenic obesity concept […”
BackgroundSelf-citationSarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
Obesity and ageing: Two sides of the same coin
Tam, B. T., Morais, J. A., & Santosa, S. (2020) · Obesity Reviews · doi:10.1111/obr.12991 · Cited by 253
“With obesity, deleterious alterations in skeletal muscle structure and metabolism may result in declines in muscle mass and function.(154)”
BackgroundLivshits, G., & Kalinkovich, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100980 · Cited by 237
Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments
Wang, M., Tan, Y., Shi, Y., Wang, X., Liao, Z., & Wei, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00568 · Cited by 231
Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives
Koliaki, C., Liatis, S., Dalamaga, M., & Kokkinos, A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00359-9 · Cited by 176
Piccoli, G. B., Cederholm, T., Avesani, C. M., Bakker, S. J. L., Bellizzi, V., Cuerda, C., Cupisti, A., Sabatino, A., Schneider, S., Torreggiani, M., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.01.018 · Cited by 146
Self-citationLong-Term Weight Loss Strategies for Obesity
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab091 · Cited by 139
“Although long-term weight loss outcomes can be confounded by age-related reductions in muscle mass (73), the Action for Health in Diabetes (Look AHEAD, BMI = 36 kgs/ m 2 ) and Diabetes Prevention Program (DPP) demonstrated that meaningful weight loss can be achieved with lifestyle modification;…”
Khadra, D., Itani, L., Tannir, H., Kreidieh, D., Masri, D. E., & Ghoch, M. E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.311 · Cited by 130
Sarcopenic Obesity: An Emerging Public Health Problem
Ji, T., Li, Y., & Ma, L. (2022) · Aging and disease · doi:10.14336/ad.2021.1006 · Cited by 124
“In SO, adipocytes accumulate in muscle tissue and other organs (heart, liver and pancreas and so on) and secrete proinflammatory cytokines (TNF-α, IL-6, IL-1 and leptin), thus leading to the infiltration of inflammatory cells and inducing insulin resistance and lipotoxicity, which directly affects skeletal muscle and…”
BackgroundDouble burden of malnutrition in persons with obesity
Barazzoni, R., & Gortan Cappellari, G. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09578-1 · Cited by 120
Self-citationGortan Cappellari, G., Guillet, C., Poggiogalle, E., Ballesteros Pomar, M. D., Batsis, J. A., Boirie, Y., Breton, I., Frara, S., Genton, L., Gepner, Y., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.02.018 · Cited by 113
Self-citationAge-related muscle anabolic resistance: inevitable or preventable?
Aragon, A. A., Tipton, K. D., & Schoenfeld, B. J. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuac062 · Cited by 93
Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s381546 · Cited by 91
“In addition, the activities of sarcopenia patients are reduced, and various factors secreted by their muscles, such as Myostatin, Irisin, IL-6, IL-8, IL-15, will in turn increase the degree of obesity.(23,24) Both sarcopenia and obesity can independently increase the risk of adverse health outcomes.”
BackgroundValenzuela, P. L., Maffiuletti, N. A., Tringali, G., De Col, A., & Sartorio, A. (2020) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-020-03228-y · Cited by 87
Prevention and treatment of sarcopenic obesity in women
Petroni, M. L., Caletti, M. T., Dalle Grave, R., Bazzocchi, A., Aparisi Gómez, M. P., & Marchesini, G. (2019) · Nutrients · doi:10.3390/nu11061302 · Cited by 82
“Metabolic lipotoxicity secondary to ectopic fat accumulation in muscle tissue, mitochondrial dysfunction and muscle stem cell dysfunction with trans-differentiation into adipose cells have also been described [12].”
BackgroundResultInfluentialKim, D., Lee, J., Park, R., Oh, C., & Moon, S. (2024) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13397 · Cited by 80
“5,6 The prevalence of sarcopenic obesity in older adults has become a signi fi cant concern, given its negative impact on quality of life, physical function and mortality.”
BackgroundCampi, R., Rebez, G., Klatte, T., Roussel, E., Ouizad, I., Ingels, A., Pavan, N., Kara, Ö., Erdem, S., Bertolo, R. G., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00781-8 · Cited by 95
“For example, patients with so-called sarcopenic obesity (which is concurrent high body fat mass and low muscle mass), who might have a poor prognosis, could not be identified through BMI assessment 58 .”
BackgroundVascular Impairment, Muscle Atrophy, and Cognitive Decline: Critical Age-Related Conditions
de Lima, E. P., Tanaka, M., Lamas, C. B., Quesada, K., Detregiachi, C. R. P., Araújo, A. C., Guiguer, E. L., Catharin, V. M. C. S., de Castro, M. V. M., Junior, E. B., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12092096 · Cited by 73
The prevalence of low muscle mass associated with obesity in the USA
Murdock, D. J., Wu, N., Grimsby, J. S., Calle, R. A., Donahue, S., Glass, D. J., Sleeman, M. W., & Sanchez, R. J. (2022) · Skeletal Muscle · doi:10.1186/s13395-022-00309-5 · Cited by 73
“A consensus on diagnostic tools and criteria is needed, as well as identification of optimal prevention and treatment options [32].”
BackgroundAssociations of sarcopenic obesity versus sarcopenia alone with functionality
Bahat, G., Kilic, C., Ozkok, S., Ozturk, S., & Karan, M. A. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.04.002 · Cited by 73
Pekař, M., Pekařová, A., Bužga, M., Holéczy, P., & Soltes, M. (2020) · Videosurgery and Other Miniinvasive Techniques · doi:10.5114/wiitm.2020.93463 · Cited by 72
“Some authors advocate the need for preventive programmes to overcome the problem of sarcopenia [11], such as the combination of aerobic and power exercises, which appears to be the most effective approach [12–14].”
BackgroundVitamin D in Osteosarcopenic Obesity
di Filippo, L., LORENZO, R. D., Giustina, A., Rovere, P. Q., & Conte, C. (2022) · Nutrients · doi:10.3390/nu14091816 · Cited by 79
“Inflammation and oxidative stress exert catabolic effects and may induce anabolic resistance in skeletal muscle, ectopic fat accumulation with fatty infiltration (myosteatosis) results in lipotoxicity, alterations in muscle stem cell may determine a shift towards adipocyte differentiation, and mitochondrial dysfunctio…”
BackgroundKanwal, S., Aliya, S., & Xin, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.558874 · Cited by 65
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 59
“Its diagnosis analyzes muscle mass (as part of a body composition analysis) and muscle function (using suitable function tests) obligatory initially and also during the disease [60,61].”
Self-citationBischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 71
“analysis) and muscle function (using suitable function tests) obligatory initially and also during the disease.(60,61) ESPEN and”
MethodSelf-citationImpact of sarcopenia in trauma and surgical patient population: A literature review
Wahlen, B. M., Mekkodathil, A. A., Al-Thani, H. A. S., & El-Menyar, A. A. (2019) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2019.10.010 · Cited by 59
Prevalence of sarcopenic obesity in adults with end-stage knee osteoarthritis
Godziuk, K., Prado, C. M. M., Woodhouse, L. J., & Forhan, M. A. (2019) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2019.05.026 · Cited by 58
Tao, X., Niu, R., Lu, W., Zeng, X., Sun, X., & Liu, C. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01493-8 · Cited by 61
“Their coexistence was de fi ned as sarcopenic obesity, where the synergistic effect may generate more adverse outcomes [5].”
Sarcopenic obesity: What about in the cancer setting?
Gortan Cappellari, G., Brasacchio, C., Laudisio, D., Lubrano, C., Pivari, F., Barrea, L., Muscogiuri, G., Savastano, S., & Colao, A. (2022) · Nutrition · doi:10.1016/j.nut.2022.111624 · Cited by 48
Reduced muscle mass as predictor of intensive care unit hospitalization in COVID-19 patients
Giraudo, C., Librizzi, G., Fichera, G., Motta, R., Balestro, E., Calabrese, F., Carretta, G., Cattelan, A. M., Navalesi, P., Pelloso, M., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253433 · Cited by 49
Self-citationThe effect of sarcopenia and sarcopenic obesity on survival in gastric cancer
Şahin, M. E. H., Akbaş, F., Yardımcı, A. H., & Şahin, E. (2023) · BMC Cancer · doi:10.1186/s12885-023-11423-y · Cited by 54
“Sarcopenic obesity is a recently coined term that describes the combination of sarcopenia and obesity, characterized by elevated body mass index (BMI), waist circumference (WC), total fat mass, body fat percentage, or visceral fat area [4].”
BackgroundKhazem, S., Itani, L., Kreidieh, D., Masri, D. E., Tannir, H., Citarella, R., & Ghoch, M. E. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15122754 · Cited by 51
“, physical activity interventions, high-protein diets and protein supplements) focused on limiting LBM deterioration as a clinical priority [12].”
BackgroundYin, T., Zhang, J.-X., Wang, F.-X., Zhao, J.-H., Zhao, Y., Liu, L., Liu, X.-Y., Zhang, Y.-H., & Zhao, Y. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s308387 · Cited by 44
Bischoff, S. C., Ockenga, J., Eshraghian, A., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Kani, H. T., Khannoussi, W., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.021 · Cited by 49
“Based on the above observations, the association between obesity and IBD may be further related to the high risk of sarcopenic obesity, i.e. the association of excess fat mass and low skeletal muscle mass and function [24 e 26], as indeed indicated by a few available reports [27].”
BackgroundSelf-citationAlalwan, T. A. (2020) · Geriatrics · doi:10.3390/geriatrics5010008 · Cited by 46
“The few available studies indeed indicate that low muscle function and mass may be associated with higher mortality in obese individuals with chronic diseases [17].”
BackgroundSarcopenic obesity diagnosis by different criteria mid-to long-term post-bariatric surgery
Vieira, F. T., Godziuk, K., Lamarca, F., Melendez-Araújo, M. S., Lima, R. M., Prado, C. M., de Carvalho, K. M. B., & Dutra, E. S. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.006 · Cited by 38
Myopenic obesity determined by visceral fat area strongly predicts long-term mortality in cirrhosis
Feng, H., Wang, X., Zhao, T., Mao, L., Hui, Y., Fan, X., Lin, L., Zhao, W., Jiang, K., Wang, B., et al. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.016 · Cited by 40
Cofano, F., Perna, G. D., Bongiovanni, D., Roscigno, V., Baldassarre, B. M., Petrone, S., Tartara, F., Garbossa, D., & Bozzaro, M. (2021) · Global Spine Journal · doi:10.1177/21925682211022313 · Cited by 43
“Lastly, recent evidence shows that ectopic lipids deposition can also compromise the turnover of muscle proteins promoting systemic and muscular oxidative stress.(157,160,161) Blood glucose concentrations could also play substantial roles with its opposing effects on immunological/cellular mechanisms.”
BackgroundThe Role of Exercise in Cancer-Related Sarcopenia and Sarcopenic Obesity
Papadopetraki, A., Giannopoulos, A., Maridaki, M., Zagouri, F., Droufakou, S., Koutsilieris, M., & Philippou, A. (2023) · Cancers · doi:10.3390/cancers15245856 · Cited by 34
“Thus, sarcopenic obese patients are characterised by the increased deposition of fat mass with the simultaneous loss of skeletal muscle mass and function [49,50].”
BackgroundRole of Adipokines in Sarcopenia
Lu, W., Feng, W., Lai, J., Yuan, D., Xiao, W., & Li, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002255 · Cited by 34
“Sarcopenia often occurs in obese patients and is called sarcopenic obesity.([14]) The main cause of sarcopenic obesity is age-related changes in metabolism and body composition, as well as the presence of obesity factors and physical diseases that are accompanied by aging.”
BackgroundThe Asia–Oceania consensus: Definitions and diagnostic criteria for sarcopenic obesity
Chen, T., Kao, H., Ogawa, W., Arai, H., Tahapary, D. L., Assantachai, P., Tham, K. W., Chan, D., Yuen, M. M. A., Appannah, G., et al. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.05.001 · Cited by 47
Bays, H. E., Golden, A., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100034 · Cited by 34
“Conversely, worsening physical inactivity coupled with an aging population may help explain why the rate of sarcopenic obesity is increasing [219].”
BackgroundAli, S. R., Nkembo, A. T., Tipparaju, S. M., Ashraf, M., & Xuan, W. (2024) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0201 · Cited by 40
Adipogenic progenitors in different organs: Pathophysiological implications
Favaretto, F., Bettini, S., Busetto, L., Milan, G., & Vettor, R. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09686-6 · Cited by 37
Self-citationDefining and diagnosing sarcopenia: Is the glass now half full?
Barazzoni, R., Cederholm, T., Zanetti, M., & Cappellari, G. G. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155558 · Cited by 38
Self-citationZembura, M., Czepczor‐Bernat, K., Dolibog, P., Dolibog, P., & Matusik, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1252853 · Cited by 43
Mwala, N. N., Borkent, J. W., van der Meij, B. S., & de van der Schueren, M. A. E. (2024) · Nutrition Research Reviews · doi:10.1017/s095442242400012x · Cited by 39
“Consequently, managing chronic conditions becomes more challenging as surgical risks increase and certain diseases suchas congestiveheartfailure,diabetes andrheumatoid arthritis may progress faster in the presence of obesity (81) .”
BackgroundAssyov, Y. S., Nedeva, I., Spassov, B., Gerganova, A., Velikov, T., Kamenov, Z. A., & Velikova, T. V. (2024) · Nutrients · doi:10.3390/nu16152560 · Cited by 34
“SO has a variety of additive negative health outcomes that impact overall functional ability as well as the overall morbidity and mortality and associated medical costs [9].”
BackgroundMECHANISMS OF ENDOCRINE DISEASE: Sarcopenia in endocrine and non-endocrine disorders
Borba, V. Z. C., Costa, T. M. D. R. L., Moreira, C. A., & Boguszewski, C. L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0937 · Cited by 33
Prevalence of sarcopenia in women at stable weight phase after Roux-en-Y gastric bypass
Buzza, A. F. B., Machado, C. A., Pontes, F. G. D. B., Sampaio, L. G., Contador, J. S., Sampaio, C. L., Radominski, R. B., Boguszewski, C. L., & Borba, V. Z. C. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000494 · Cited by 29
“Bariatric surgery almost invariably predisposes patients to experience sarcopenic obesity onset, at least at the early rapid weight loss phase, due to significantly negative energy balance associated with this procedure (18).”
BackgroundCare of the Patient After Metabolic and Bariatric Surgery
Bramante, C., Wise, E., & Chaudhry, Z. (2022) · Annals of Internal Medicine · doi:10.7326/aitc202205170 · Cited by 28
Overweight/obesity in adolescents with phenylketonuria: protective and predisposing factors
Silveira, A. M., Lima, P. L., Alves, M. R. A., Soares, R. D. L., Kanufre, V. D. C., Rodrigues, V. D. M., Starling, A. L. P., Norton, R. D. C., & de Aguiar, M. J. B. (2021) · Jornal de Pediatria · doi:10.1016/j.jped.2021.04.009 · Cited by 29
“The assessment of overweight/obesity in PKU presents several difficulties due to the recent increase in the prevalence of obesity worldwide in all age groups and because of the different factors involved in this increment.(9,13,14) A similar phenomenon has been observed in Brazil, and it is difficult to define whether…”
BackgroundJalabert, A., Reininger, L., Berger, E., Couté, Y., Meugnier, E., Forterre, A. V., Errazuriz-Cerda, E., Géloën, A., Aouadi, M., Bouzakri, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00983-3 · Cited by 33
Arnáiz, E. G., Cobo, D. A., Estébanez, B., Galindo, D. E. B., de la Maza, B. P., Fondo, A. U., Pons, C. D., Cuevas, M. J., & Ballesteros-Pomar, M. D. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.03.015 · Cited by 28
Female obesity: clinical and psychological assessment toward the best treatment
Guglielmi, V., Grave, R. D., Leonetti, F., & Solini, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1349794 · Cited by 44
Anesthesia for the elderly: a narrative review
Olotu, C. (2021) · Minerva Anestesiologica · doi:10.23736/s0375-9393.21.15388-x · Cited by 29
Food insecurity as a risk factor of sarcopenic obesity in older adults
Fonseca-Pérez, D., Arteaga-Pazmiño, C., Maza-Moscoso, C. P., Flores-Madrid, S., & Álvarez-Córdova, L. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1040089 · Cited by 23
Rizvi, A. A., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60101648 · Cited by 37
“The increasing prevalence of obesity became a compounding factor in ageing-related sar-copenia [5].”
BackgroundYoussef, L., Granet, J., Marcangeli, V., Dulac, M., Hajj‐Boutros, G., Reynaud, O., Buckinx, F., Gaudreau, P., Morais, J. A., Mauriège, P., et al. (2022) · Healthcare · doi:10.3390/healthcare10071346 · Cited by 36
“Sarcopenic obesity is considered a double health burden as it is associated with major adverse health outcomes including the development of frailty and disability, due to low muscle function and mass and an excess in adiposity levels [3].”
BackgroundLuo, X., Cai, B., & Jin, W. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0035 · Cited by 29
“29 Research on sarcopenic obesity is in its early stages, and its definition and diagnostic criteria remain unified.”
Siervo, M., Rubele, S., Shannon, O. M., Prado, C. M. M., Donini, L. M., Zamboni, M. M., Homayounfar, R., Farjam, M., Faghih, S., & Mazidi, M. (2021) · Clinical Obesity · doi:10.1111/cob.12459 · Cited by 24
“Unfavourable changes in nutrient intake and physical inactivity are key risk factors for the increasing worldwide trends of obesity and sarcopenia.(1) Sarcopenic obesity (SO) is characterised by the concomitant presence in the same individual of an excess of fat mass (FM) and reduced fat free mass (FFM), which are bot…”
BackgroundOzeki, S., Takeuchi, K., Yasuoka, M., Kamiji, K., Kojima, T., Waguri‐Nagaya, Y., Ojima, T., Kondo, K., Wakai, K., & Kojima, M. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104455 · Cited by 22
Caccialanza, R., Formisano, E., Klersy, C., Ferretti, V. V., Ferrari, A., Demontis, S., Mascheroni, A., Masi, S., Crotti, S., Lobascio, F., et al. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.06.020 · Cited by 26
“Nonetheless, obesity per-se may mask the risk of malnutrition but increased risk could be determined by concomitant sarcopenia [32].”
Diet Quality and Measures of Sarcopenia in Developing Economies: A Systematic Review
Ramadas, A., Law, H. H., Krishnamoorthy, R., Ku, J. W. S., Mohanty, P., Lim, M. Z. C., & Shyam, S. (2022) · Nutrients · doi:10.3390/nu14040868 · Cited by 23
Ispoglou, T., Wilson, O. J., McCullough, D., Aldrich, L., Ferentinos, P. P., Lyall, G. K., Stavropoulos‐Kalinoglou, A., Duckworth, L. C., Brown, M. A., Sutton, L., et al. (2023) · Biology · doi:10.3390/biology12070892 · Cited by 29
Khadra, D., Itani, L., Chebaro, Y., Obeid, M., Jaber, M., Ghanem, R., Ayton, A. K., Kreidieh, D., Masri, D. E., Kimura, A., et al. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16666200214104122 · Cited by 24
“metabolic and cardiovascular diseases) [5, 6, 8-15], with the speculation that the two components of SO, namely the increase of fat deposition and the reduction in muscle mass and strength, seem to act synergistically to increase the adverse consequences on health, but this hypothesis has not been confirmed [16-18].”
BackgroundObese Animals as Models for Numerous Diseases: Advantages and Applications
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Medicina · doi:10.3390/medicina57050399 · Cited by 26
Borba, V. Z. C., & Costa, T. M. D. R. L. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0084 · Cited by 21
“Although several pharmacological molecules have been considered for sarcopenic obesity treatment, they are still not recommended due to a lack of strong evidence of efficacy (69) (Figure 2).”
Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives
Kottorou, A. E., Dimitrakopoulos, F.-I. D., & Tsezou, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101101 · Cited by 24
FGF19 protects against obesity-induced bone loss by promoting osteogenic differentiation
Guo, A., Li, K., Tian, H., Tao, B., Xiao, Q., & Jiang, D. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112524 · Cited by 26
Zeng, X., Ren, D., Li, D., Du, H., & Yang, X. (2022) · Food & Function · doi:10.1039/d2fo02257e · Cited by 25
Sarcopenic obesity: patterns and paradoxes
Drapkina, O. M., Budnevsky, A. V., Ovsyannikov, Е. S., Васильевна, К. А., & Дробышева, Е. С. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212401173 · Cited by 21
Palmas-Candia, F. X., Ciudin, A., Guerra, R., Eiroa, D., Coll, C. E., Rosón, N., Burgos, R., & Simó, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1161116 · Cited by 23
Association of central obesity and high body mass index with function and cognition in older adults
Merchant, R. A., Wong, M. W. K., Lim, J. Y., & Morley, J. E. (2021) · Endocrine Connections · doi:10.1530/ec-21-0223 · Cited by 21
Li, R., Chen, X., Tang, H., Luo, S., Lian, R., Zhang, W., Zhang, X., Hu, X., & Yang, M. J. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105557 · Cited by 20
Jin, H., Oh, H., Nah, S.-Y., & Lee, B.-Y. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.10.003 · Cited by 18
“Sarcopenic obesity is a combined accumulation of body fat and abnormal skeletal muscle loss, which is associated with muscle dysfunction and further metabolic disorders [43].”
BackgroundLorenzo, P. M., & Crujeiras, A. B. (2021) · Food & Function · doi:10.1039/d0fo01984d · Cited by 16
Vaillant, M.-F., Agier, L., Martineau, C., Philipponneau, M., Romand, D., Masdoua, V., Behar, M., Nesseler, C., Achamrah, N., Laubé, V., et al. (2021) · Nutrition · doi:10.1016/j.nut.2021.111433 · Cited by 19
“[19], to be more conscious of public health messages regarding the benefits of losing weight, than of the importance of preserving their muscle mass and function.”
Gao, F., Zheng, K. I., Zhu, P., Li, Y., Ma, H., Li, G., Tang, L., Rios, R. S., Liu, W., Pan, X.-Y., et al. (2020) · British Journal Of Nutrition · doi:10.1017/s0007114520004559 · Cited by 16
“Low muscle mass has a strong negative prognostic impact in obese individuals and may lead to increased morbidity and mortality(27).”
BackgroundLee, H., Chung, H. S., Kim, Y. J., Choi, M. K., Roh, Y. K., Yu, J. M., Oh, C., Kim, J. M., & Moon, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1257902 · Cited by 22
Falconer, E. A., Harris, D. A., Prooyen, A. M. V., Hicks, J. L., Singh, A., Davis, S. S., Lin, E., Sharma, J., Pollock, J., Samarov, D. V., et al. (2021) · Surgical Endoscopy · doi:10.1007/s00464-021-08343-y · Cited by 15
Zhou, Y., Su, X., Tan, H., & Xiao, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02439-3 · Cited by 15
Dias, K. M., Herdman, T. H., Ferretti‐Rebustini, R. E. D. L., Lopes, C. T., & dos Santos, E. R. (2020) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2020ao5445 · Cited by 14
“Braden scale(10) Pressure injury risk Nurse researcher Resident 6 subscales, namely: sensory perception, activity, mobility, moisture, nutrition, friction or shear Total score can vary from 6-23 points, and the patients are classified as follows: very high risk of pressure injury (≤9 points), high risk (10-12), modera…”
BackgroundBattista, F., Belligoli, A., Neunhäeuserer, D., Gasperetti, A., Bettini, S., Compagnin, C., Marchese, R., Quinto, G., Bergamin, M., Vettor, R., et al. (2021) · Obesity Facts · doi:10.1159/000517589 · Cited by 18
Self-citationTong, Q., Wang, X., Sheng, Y., Chen, S., Lai, B., Lv, R., & Yu, J. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210143 · Cited by 14
“In addition to aging, the potential factors associated with sarcopenia include chronic inflammation, malnutrition, lack of exercise, and hormonal dysregulation[3].”
BackgroundUsefulness of Muscle Ultrasound to Study Sarcopenic Obesity: A Pilot Case-Control Study
Simó-Servat, A., Ibarra, M., Libran, M., Rodríguez, S., Perea, V., Quirós, C., Orois, A., Pérez, N., Simó, R., & Barahona, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102886 · Cited by 16
“and EASO have recently recognized SO as a priority for clinical research [10,11].”
BackgroundSharma, A. R., Chatterjee, S., Lee, Y., & Lee, S. (2023) · Aging and Disease · doi:10.14336/ad.2023.00903 · Cited by 30
“Factors, including ethnicity, method of diagnosis, and the subjects chosen for the study, make it very tough to provide a clear hypothesis regarding the prevalence of sarcopenia, making it a concerning health issue in the public sector [14].”
BackgroundQiu, L., Ren, Y., Li, J., Li, M., Li, W., Qin, L., Ning, C., Zhang, J., & Gao, F. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.06.003 · Cited by 14
Cardoso, P., Santos, T. V., Ramon‐Krauel, M., Pais, S., & Sousa‐Coelho, A. L. D. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07816-6 · Cited by 21
“Extended author information available on the last page of the article Sarcopenic obesity (SO) is defined as a clinical condition in which an individual, characterized by having excess adiposity, has reduced lean body mass [25–27].”
Rivera-Carranza, T., Nájera-Medina, O., Bojalil‐Parra, R., Rodríguez-López, C. P., Zúñiga-León, E., Girón, A. L.-T., & Azaola‐Espinosa, A. (2023) · PeerJ · doi:10.7717/peerj.15465 · Cited by 14
Pellegrini, M., Itani, L., Rossi, A. P., Kreidieh, D., El Masri, D., Tannir, H., & El Ghoch, M. (2022) · Healthcare · doi:10.3390/healthcare10102042 · Cited by 11
“For this reason, international scientific societies and associations addressing nutrition and obesity have recommended the consideration of SO as a clinical research priority [4].”
BackgroundSarcobesity Index Predicts Poor Disease-Specific Survival After Resection for Colorectal Cancer
Conti, C., Turri, G., Gecchele, G., Conci, S., Zamboni, G. A., Ruzzenente, A., Guglielmi, A., & Pedrazzani, C. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.06.029 · Cited by 15
Yamagishi, S., Okamura, Y., Kang, W., Shindate, M., Kochi, M., Mitsuka, Y., Watabe, M., Yoshida, N., Ikarashi, M., Yamazaki, S., et al. (2023) · Digestive Surgery · doi:10.1159/000531797 · Cited by 14
“Sarcopenic obesity is a clinical and functional disorder with a comorbidity of obesity and sarcopenia [18, 28].”
BackgroundGüner, M., Öztürk, Y., Ceylan, S., Baş, A. O., Koca, M., Balcı, C., Doğu, B. B., Cankurtaran, M., & Halil, M. G. (2024) · European Geriatric Medicine · doi:10.1007/s41999-024-01024-8 · Cited by 13
Immunogenetic Aspects of Sarcopenic Obesity
Mazurkiewicz, Ł., Czernikiewicz, K., & Grygiel‐Górniak, B. (2024) · Genes · doi:10.3390/genes15020206 · Cited by 14
“In the literature SO is defined as excess fat mass and sarcopenia [43].”
BackgroundSarcopenia and sarcopenic obesity among community-dwelling Peruvian adults: A cross-sectional study
Flores-Flores, O., Zevallos-Morales, A., Pollard, S. L., Checkley, W., Siddharthan, T., Hurst, J. R., Bernabé‐Ortiz, A., Runzer-Colmenares, F. M., Witham, M. D., & Parodi, J. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300224 · Cited by 15
“Similar negative impacts are associated with obesity, the prevalence of which has increased, particularly in low-middle income settings, posing social, economic, and healthcare challenges [5].”
BackgroundLampignano, L., Bortone, I., Castellana, F., Donghia, R., Guerra, V., Zupo, R., Pergola, G. D., Masi, M. D., Giannelli, G., Lozupone, M., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182412979 · Cited by 12
“Sarcopenic obesity is gaining a lot of interest in the medical community, and in clinical practice the number of studies focusing on sarcopenic obesity with regard to risk evaluation and treatment effects seems to outnumber studies on sarcopenia in general [9].”
Background
Metadata
- Authors
- Barazzoni, R., Bischoff, S., Boirie, Y., Busetto, L., Cederholm, T., Dicker, D., Toplak, H., Van Gossum, A., Yumuk, V., & Vettor, R.
- Affiliations
- University of Trieste (IT)
- University of Hohenheim (DE)
- University of Padua (IT)
- Uppsala University (SE)
- Tel Aviv University (IL)
- Medical University of Graz (AT)
- Istanbul University-Cerrahpaşa (TR)
- ORCID
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 294-305
- ISSN
- 1662-4025 (ISSN-L)
- 1662-4033
- PMC
- PMC6189532
- OpenAlex
- W2883874811
- Cited by
- 244
- References
- 92
- Citations by year
- 2026: 33 · 2025: 26 · 2024: 31 · 2023: 46 · 2022: 39 · 2021: 37 · 2020: 18 · 2019: 11 · 2018: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Obesity Facts (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by-nc-nd)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- sarcopenic obesity, obesity, skeletal muscle mass, muscle function, frailty, body composition, diagnostic criteria, nutritional therapy, weight loss, chronic comorbidities
- MeSH terms
- Body Composition, Diet, Humans, Life Style, Obesity, Risk Factors, Prevalence, Muscle, Skeletal, Adiposity, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.